DynPort’s clinical stage recombinant Yersinia pestis rF1V plague vaccine to benefit from FDA Orphan Drug Designation FALLS CHURCH, Va., March 8, 2017 /PRNewswire/ — CSRA Inc. (NYSE: CSRA) today announced that […]
https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png00Christiane Truelovehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngChristiane Truelove2017-03-08 12:35:082017-03-08 12:35:08FDA Grants Orphan Drug Designation to CSRA’s DynPort Vaccine Company for Plague Vaccine
